VYRIAD Trademark
Trademark Overview
On Tuesday, August 8, 2023, a trademark application was filed for VYRIAD with the United States Patent and Trademark Office. The USPTO has given the VYRIAD trademark a serial number of 98122765. The federal status of this trademark filing is OPPOSITION PENDING as of Thursday, November 7, 2024. This trademark is owned by Vyriad, Inc.. The VYRIAD trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use for the treatment of cancer,
cardiovascular diseases, and heritable genetic diseases; medicinal preparations for use in oncology; pharmaceutical preparations
for the treatment of immune system related diseases and disorders, namely, cancer and cardiovascular diseases and heritable
genetic diseases; pharmaceutical preparations for treatment of genetic and heritable genetic diseases; cellular pharmaceutical
preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T)
cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; pharmaceutical
preparations for use in oncology; all of the foregoing to exclude infectious diseases
Medical and scientific research and development in the fields of cancer treatment and oncolytic virotherapy; research and
development of bio-pharmaceuticals for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medical
and scientific research in the fields of genetics and oncology; research and development of technology in the fields of stem cells
and stem cell therapy for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; development of
genetic therapies and chimeric antigen receptor cell (CAR-T) cell therapies for the treatment of cancer, cardiovascular diseases,
and heritable genetic diseases; scientific research and development of cell therapies, namely, chimeric antigen receptor T-cells
(CAR-T) to cure solid tumor cancers and other cancers; medical and scientific research services in the fields of genetics, cell
therapy, oncology, immuno-oncology; all of the foregoing to exclude infectious diseases
General Information
| Serial Number | 98122765 |
| Word Mark | VYRIAD |
| Filing Date | Tuesday, August 8, 2023 |
| Status | 774 - OPPOSITION PENDING |
| Status Date | Thursday, November 7, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 8, 2024 |
Trademark Statements
| Goods and Services | Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use for the treatment of cancer,
cardiovascular diseases, and heritable genetic diseases; medicinal preparations for use in oncology; pharmaceutical preparations
for the treatment of immune system related diseases and disorders, namely, cancer and cardiovascular diseases and heritable
genetic diseases; pharmaceutical preparations for treatment of genetic and heritable genetic diseases; cellular pharmaceutical
preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T)
cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; pharmaceutical
preparations for use in oncology; all of the foregoing to exclude infectious diseases |
| Goods and Services | Medical and scientific research and development in the fields of cancer treatment and oncolytic virotherapy; research and
development of bio-pharmaceuticals for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medical
and scientific research in the fields of genetics and oncology; research and development of technology in the fields of stem cells
and stem cell therapy for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; development of
genetic therapies and chimeric antigen receptor cell (CAR-T) cell therapies for the treatment of cancer, cardiovascular diseases,
and heritable genetic diseases; scientific research and development of cell therapies, namely, chimeric antigen receptor T-cells
(CAR-T) to cure solid tumor cancers and other cancers; medical and scientific research services in the fields of genetics, cell
therapy, oncology, immuno-oncology; all of the foregoing to exclude infectious diseases |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 8, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | Wednesday, October 26, 2016 |
| First Use In Commerce Date | Wednesday, October 26, 2016 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 8, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | Wednesday, October 26, 2016 |
| First Use In Commerce Date | Wednesday, October 26, 2016 |
Trademark Owner History
| Party Name | Vyriad, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Rochester, MN 55901 |
| Party Name | Vyriad, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Rochester, MN 55901 |
Trademark Events
| Event Date | Event Description |
| Friday, September 8, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, August 11, 2023 | NEW APPLICATION ENTERED |
| Monday, April 8, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, April 10, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, April 10, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, April 10, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, June 14, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, June 14, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, June 14, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, September 5, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, September 18, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, October 3, 2024 | TEAS POST PUBLICATION AMENDMENT RECEIVED |
| Tuesday, October 8, 2024 | PUBLISHED FOR OPPOSITION |
| Monday, October 21, 2024 | ASSIGNED TO PETITION STAFF |
| Tuesday, October 8, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Thursday, November 7, 2024 | OPPOSITION PAPERS RECEIVED AT TTAB |
| Thursday, November 7, 2024 | OPPOSITION INSTITUTED NO. 999999 |
| Monday, November 4, 2024 | POST PUBLICATION AMENDMENT - ENTERED |
| Wednesday, May 7, 2025 | OPPOSITION DISMISSED NO. 999999 |
